Epitomee Medical : Presentation- September 2023

Ingestible Therapeutic Platform

Treating Chronic Disease through the GI Tract

September 2023

This presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the "Company") and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business required for any decision concerning an investment in the Company's securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute "forward-looking statements" as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by or who contracts the Company and its services, change in the overall economy; the duration and severity of the COVID-19 (coronavirus) pandemic and its impact on the Company and on local and global economy and the Company's ability to manage and develop its business. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement its investment strategy or achieve any investment objective.

Shaping Your Health | 2

Management Team

Shimon Eckhouse, PhD	Dan Hashimshony, PhD
Co-founder and Chairman	Chief Executive Officer

Founder of Syneron Nasdaq:ELOS & Lumenis Nasdaq:LMNS, Sofwave Medical TLV: SOFW and others

Founder & CEO-Dune Medical Devices Chief Scientist X-technologies, and others

Gal Aharonowitz	Yael Kenen, PhD	Gil Cohen, PhD	Maya Gabrieli, CPA	Safi Landskroner	Dr. Ruthie Amir, MD.
COO	VP Clinical Affairs	VP R&D	VP Finance	VP Business Development	Chief Medical & Regulatory Officer
SHL, VP R&D Lumenis,	TEVA, Global Clinical Drug	SCO Dune Medical Devices,	Plastopil Hazorea LTD,	Dexcel Pharma, Mapi Pharma,	Global VP Regulatory
GM Israel	Development Director	Hebrew University of Jerusalem	KPMG	Chartwell Pharmaceuticals	Syneron, Sofwave Medical
Dune medical
					Shaping Your Health | 3

Company Highlights

Breakthrough Tech	Market Potential	Strategic Alliances
Ingestible, Shapeshifting Platform	Multi Billion $ Market	With Global Conglomerates
•	Creates self-ingested, swallowable	•	Weight management >$200B	•	Weight management:
	devices that act along the GI tract		(Commercialization stage)		Global commercialization
•	Achieves therapeutic outcomes in	•	Biologics delivery >300B		and marketing with Nestle
	prevalent diseases		(Growth engine)	•	Biologics: Advancing collaborations
					with big pharma on biologic oral delivery

Global Commercialization	Protected Innovation	Strong Cash Position
Regulatory Progress	Intellectual Property	IPO TASE Dec 2021
• Cleared in: Europe, Israel	• 30 granted patents	• Current cash balance ~ $38M
• Completed pivotal study for FDA 510(k)	• 12 pending patents
showing great clinical outcomes

• Targeting FDA clearance & market launch in 2024

Shaping Your Health | 4

A Platform Technology with Various Applications

Adaptable in function, duration and location of operation

1	Weight Management:
active in the stomach

ORAL ADMINISTRATION	TARGETED DEPLOYMENT
Easy ingestion with no	Precise delivery to specific
clinical procedures	therapeutic location

TRANSIENT ACTIVITY	SAFE
Temporary engagement	Designed with patient
2		Oral Biologics: drug carrier for
and complete clearance	safety at the forefront
	delivery in the small intestine

Shaping Your Health | 5